查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574931

浸潤性乳管癌治療的市場規模、佔有率和趨勢分析報告：按治療、類型、分銷管道、地區和細分市場預測，2024-2030年

Invasive Ductal Carcinoma Treatment Market Size, Share & Trends Analysis Report By Therapy (Targeted, Hormonal), By Type, By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

浸潤性乳管癌治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，2024年至2030年，全球浸潤性乳管癌治療市場規模將以8.5%的複合年成長率擴大，預計2030年達到152.1億美元。

該市場涵蓋了有助於管理和護理這種常見乳癌患者的多種因素。

人們對乳癌及其早期發現的認知不斷提高，導致更多的女性接受定期篩檢。美國癌症協會報告稱，定期進行乳房X光攝影檢查可以在早期、可治療的階段發現乳癌。這種認知的提高有助於早期診斷，隨著發現更多病例，對有效 IDC 治療的需求也在增加。

政府核准流程包括美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 等監管機構的嚴格評估。這些機構在核准之前評估臨床試驗資料，以確保新治療方法的安全性和有效性。例如，2024年3月，Astra Zeneca的Truqap（capivasertib）將適用於荷爾蒙受體陽性、HER2陰性、PIK3CA、AKT1或PTEN突變以及內分泌治療後疾病進展的不可切除或復發性乳癌的成人患者。它已在日本與Faslodex（氟維司群）一起被核准用於患者的治療。

侵襲性導管癌治療市場報告亮點

  • 從治療方法來看，標靶治療佔市場主導地位，2023年銷售額佔有率最大，為64.24%。隨著製藥公司繼續投資開發新型分子標靶藥物和聯合治療，分子標靶治療有望保持其在浸潤性乳管癌治療中的領先地位。
  • 從類型來看，荷爾蒙受體佔市場主導地位，2023 年銷售額佔有率最大，為 65.37%。對個人化醫療的認知和重視的提高正在加強荷爾蒙受體治療市場。隨著醫療保健提供者越來越依賴生物標記測試來為個別患者量身定做治療方案，識別荷爾蒙受體狀態對於治療計劃變得至關重要。
  • 從銷售管道來看，醫院藥局佔據市場主導地位，2023年銷售佔有率最大，為45.45%。這一優勢是由多種因素推動的，包括對在患者接受全面護理的醫院環境中進行的化療和標靶治療的依賴增加。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章浸潤性乳管癌治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 浸潤性乳管癌治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章浸潤性乳管癌治療市場：治療評估與趨勢分析

  • 全球浸潤性乳管癌治療市場：治療儀表板
  • 全球浸潤性乳管癌治療市場：治療變異分析
  • 全球浸潤性乳管癌治療市場：按收益的治療
  • 標靶治療
  • 荷爾蒙療法
  • 化療
  • 免疫療法

第5章浸潤性乳管癌治療市場：類型估計與趨勢分析

  • 全球浸潤性乳管癌治療市場：類型儀表板
  • 全球浸潤性乳管癌治療市場：類型變異分析
  • 全球浸潤性乳管癌治療市場：按類型分類的收益
  • 荷爾蒙受體
  • HER2+

第6章浸潤性乳管癌治療市場：通路估計與趨勢分析

  • 全球浸潤性乳管癌治療市場：通路儀表板
  • 全球浸潤性乳管癌治療市場：通路波動分析
  • 全球浸潤性乳管癌治療市場：按通路分類的收益
  • 醫院藥房
  • 零售藥房
  • 其他

第7章浸潤性乳管癌治療市場：按治療、類型和通路分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 2023年主要企業市場佔有率分析
    • Novartis AG
    • Pfizer
    • Merck KGaA
    • Janssen Global Services, LLC
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca
    • AbbVie Inc.
    • Bristol-Myers Squibb Company
    • Macrogenics, Inc.
    • Celldex Therapeutics
Product Code: GVR-4-68040-444-6

Invasive Ductal Carcinoma Treatment Market Growth & Trends:

The global invasive ductal carcinoma treatment market size is anticipated to reach USD 15.21 billion by 2030, expanding at a CAGR of 8.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a wide range of elements that contribute to the management and care of patients diagnosed with this common form of breast cancer.

Increased awareness about breast cancer and its early detection led to more women undergoing regular screenings. The American Cancer Society reports that regular mammograms can detect breast cancer at an earlier stage when it is more treatable. This heightened awareness contributes to earlier diagnosis and increases the demand for effective IDC treatments as more cases are identified.

The government approval process involves rigorous evaluation by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These agencies assess clinical trial data to ensure that new therapies are safe and effective before approval. For instance, in March 2024, AstraZeneca's Truqap (capivasertib) received approval in Japan for use alongside Faslodex (fulvestrant) to treat adult patients with unresectable or recurrent breast cancer that is hormone receptor-positive, HER2-negative, and has alterations in PIK3CA, AKT1, or PTEN after they experienced disease progression following endocrine therapy.

Invasive Ductal Carcinoma Treatment Market Report Highlights:

  • Based on therapy, targeted therapy dominated the market with the largest revenue share of 64.24% in 2023. As pharmaceutical companies continue to invest in developing novel targeted agents and combination therapies, targeted therapy is expected to maintain its leading position in the IDC treatment landscape.
  • Based on type, hormone receptors dominated the market with the largest revenue share of 65.37% in 2023. The growing awareness and emphasis on personalized medicine are enhancing the market for hormone receptor therapies. As healthcare providers increasingly utilize biomarker testing to tailor treatments to individual patients, identifying hormone receptor status has become crucial in treatment planning.
  • Based on distribution channel, hospital pharmacies dominated the market with the largest revenue share of 45.45% in 2023. This dominance is driven by several factors, including the increasing reliance on chemotherapy and targeted therapies administered in hospital settings, where patients receive comprehensive care.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy
    • 1.2.2. Type
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Therapy Outlook
    • 2.2.2. Type Outlook
    • 2.2.3. Distribution Channel Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Invasive Ductal Carcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increased Incidence & Prevalence Rate Of Cancer Worldwide
      • 3.2.1.2. High Investment In R&D
      • 3.2.1.3. Technological Advancement In Cancer Biology & Pharmacology
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Stringent Regulatory Guidelines
      • 3.2.2.2. Expiry Of Patented Drugs
      • 3.2.2.3. Complications Associated With Chemotherapy
  • 3.3. Invasive Ductal Carcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Invasive Ductal Carcinoma Treatment Market: Therapy Estimates & Trend Analysis

  • 4.1. Global Invasive Ductal Carcinoma Treatment Market: Therapy Dashboard
  • 4.2. Global Invasive Ductal Carcinoma Treatment Market: Therapy Movement Analysis
  • 4.3. Global Invasive Ductal Carcinoma Treatment Market by Treatments, Revenue
  • 4.4. Targeted Therapy
    • 4.4.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Abemaciclib
      • 4.4.2.1. Abemaciclib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Ado-Trastuzumab Emtansine
      • 4.4.3.1. Ado-Trastuzumab Emtansine market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Everolimus
      • 4.4.4.1. Everolimus market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Trastuzumab
      • 4.4.5.1. Trastuzumab market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Ribociclib
      • 4.4.6.1. Ribociclib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.7. Palbociclib
      • 4.4.7.1. Palbociclib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.8. Pertuzumab
      • 4.4.8.1. Pertuzumab market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.9. Olaparib
      • 4.4.9.1. Olaparib market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.10. Others
      • 4.4.10.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Hormonal Therapy
    • 4.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.2. Selective Estrogen Receptor Modulators (SERMs)
      • 4.5.2.1. Selective estrogen receptor modulators (SERMs) market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.3. Aromatase Inhibitors
      • 4.5.3.1. Aromatase inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.5.4. Estrogen Receptor Down regulators (ERDs)
      • 4.5.4.1. Estrogen receptor down regulators (ERDs) market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Chemotherapy
    • 4.6.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Immunotherapy
    • 4.7.1. Immunotherapy market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Invasive Ductal Carcinoma Treatment Market: Type Estimates & Trend Analysis

  • 5.1. Global Invasive Ductal Carcinoma Treatment Market: Type Dashboard
  • 5.2. Global Invasive Ductal Carcinoma Treatment Market: Type Movement Analysis
  • 5.3. Global Invasive Ductal Carcinoma Treatment Market Estimates and Forecasts, By Type, Revenue (USD Million)
  • 5.4. Hormone Receptor
    • 5.4.1. Hormone receptor market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. HER2+
    • 5.5.1. HER2+ market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Invasive Ductal Carcinoma Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Invasive Ductal Carcinoma Treatment Market: Distribution Channel Dashboard
  • 6.2. Global Invasive Ductal Carcinoma Treatment Market: Distribution Channel Movement Analysis
  • 6.3. Global Invasive Ductal Carcinoma Treatment Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Invasive Ductal Carcinoma Treatment Market: Regional Estimates & Trend Analysis by Therapy, Type, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key company market share analysis, 2023
    • 8.2.3. Novartis AG
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Pfizer
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Merck KGaA
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Janssen Global Services, LLC
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. F. Hoffmann-La Roche Ltd.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. AstraZeneca
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. AbbVie Inc.
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Bristol-Myers Squibb Company
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Macrogenics, Inc.
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Celldex Therapeutics
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 4 North America Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 5 North America Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 7 U.S. Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 8 U.S. Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 10 Canada Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 11 Canada Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 13 Mexico Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 17 Europe Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 18 Europe Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 20 Germany Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 21 Germany Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 23 UK Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 24 UK Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 26 France Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 27 France Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 29 Italy Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 30 Italy Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 32 Spain Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 33 Spain Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 35 Denmark Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 38 Sweden Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 41 Norway Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 42 Norway Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 48 China Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 49 China Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 51 Japan Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 52 Japan Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 54 India Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 55 India Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 57 South Korea Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 60 Australia Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 61 Australia Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 63 Thailand Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 67 Latin America Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 70 Brazil Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 73 Argentina Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 74 Argentina Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Invasive ductal carcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 77 MEA Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 78 MEA Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 80 South Africa Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 81 South Africa Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 86 UAE Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 87 UAE Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Invasive ductal carcinoma treatment market, by therapy, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Invasive ductal carcinoma treatment market, by type, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Invasive ductal carcinoma treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Invasive ductal carcinoma treatment market: market outlook
  • Fig. 7 Invasive ductal carcinoma treatment competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Invasive ductal carcinoma treatment market driver impact
  • Fig. 11 Invasive ductal carcinoma treatment market restraint impact
  • Fig. 12 Invasive ductal carcinoma treatment market: therapy movement analysis
  • Fig. 13 Invasive ductal carcinoma treatment market: therapy outlook and key takeaways
  • Fig. 14 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Abemaciclib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Ado-trastuzumab emtansine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Everolimus market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Trastuzumab market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Ribociclib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Palbociclib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Pertuzumab market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Olaparib market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Hormonal therapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Selective estrogen receptor modulators (SERMs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Aromatase inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Estrogen receptor down regulators (ERDs) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Invasive ductal carcinoma treatment market: type movement analysis
  • Fig. 31 Invasive ductal carcinoma treatment market: type outlook and key takeaways
  • Fig. 32 Hormone receptor market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 HER2+ market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Invasive ductal carcinoma treatment market: distribution channel movement analysis
  • Fig. 35 Invasive ductal carcinoma treatment market: distribution channel outlook and key takeaways
  • Fig. 36 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Global Invasive ductal carcinoma treatment market: Regional movement analysis
  • Fig. 40 Global Invasive ductal carcinoma treatment market: Regional outlook and key takeaways
  • Fig. 41 Global Invasive ductal carcinoma treatment market share and leading players
  • Fig. 42 North America, by country
  • Fig. 43 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. key country dynamics
  • Fig. 45 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Canada key country dynamics
  • Fig. 47 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Mexico key country dynamics
  • Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 UK key country dynamics
  • Fig. 52 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Germany key country dynamics
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 France key country dynamics
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Italy key country dynamics
  • Fig. 58 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Spain key country dynamics
  • Fig. 60 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Denmark key country dynamics
  • Fig. 62 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Sweden key country dynamics
  • Fig. 64 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Norway key country dynamics
  • Fig. 66 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 China key country dynamics
  • Fig. 69 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Japan key country dynamics
  • Fig. 71 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 India key country dynamics
  • Fig. 73 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Thailand key country dynamics
  • Fig. 75 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 South Korea key country dynamics
  • Fig. 77 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Australia key country dynamics
  • Fig. 79 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Brazil key country dynamics
  • Fig. 82 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Argentina key country dynamics
  • Fig. 84 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 South Africa key country dynamics
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Saudi Arabia key country dynamics
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 UAE key country dynamics
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Kuwait key country dynamics
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 Market share of key market players- Invasive ductal carcinoma treatment market